What does the mechanism of mazdutide predict that SURMOUNT-4 did not test?

Numbers first: mazdutide · SURMOUNT-4.

I suspect the usual explanation for this is wrong, or at least incomplete.

I am aware this may have a boring answer. I would still like the boring answer stated clearly.

What is actually going on here, physically?

Specifically, GLP-1R is a class B G-protein-coupled receptor signalling predominantly through Gs and cyclic AMP, and most of the interesting pharmacology in this class is about where that signalling happens rather than how hard it is driven.

Amylin co-agonism adds to a GLP-1 effect rather than duplicating it because the two act through different circuits: amylin signals through the area postrema via calcitonin receptor complexes, GLP-1 through both the area postrema and the arcuate nucleus. Two non-redundant satiety signals summate, which is the design rationale for a co-formulation rather than a higher dose of either.

What the glucagon arm of a tri-agonist adds is energy expenditure and hepatic fat mobilisation; what it costs is glycaemic control and an increase in heart rate. That is why the tri-agonists show a steeper weight-loss curve and why their development requires more care around cardiac and glycaemic endpoints than a pure GLP-1 agonist does.

The chemistry is the interesting part and it is also the well-documented part. Read the medicinal chemistry papers; they are short and they explain the design.

More usefully, two structural interventions do the work: substitution at the DPP-4 cleavage site to stop enzymatic degradation, and a fatty-acid chain to bind serum albumin and create a slowly released reservoir. Remove either and you are back to a compound requiring continuous infusion.

The Aib substitution at position 8 replaces alanine with α-aminoisobutyric acid, which is sterically hindered enough that dipeptidyl peptidase-4 cannot cleave the N-terminal dipeptide. That single change takes the half-life from minutes to hours. The C18 diacid on a linker at Lys26 then binds albumin reversibly, which both shields the molecule from renal filtration and creates a depot that releases slowly — taking hours to about a week.

It helps to be literal here: receptor desensitisation as a plateau mechanism is plausible and poorly evidenced. GLP-1R internalises on agonist binding and recycles, and biased agonists that internalise less have been argued to sustain signalling better. Whether any of that operates at the timescale of a four-month clinical plateau — against the much simpler explanation that energy expenditure fell with mass — is not established.

Worth noting that receptor pharmacology measured in a transfected cell line is a starting point, not a physiological measurement, and potency ratios do not transfer cleanly in vivo.

Structure predicts pharmacokinetics reliably and clinical effect unreliably. Keep the two claims separate.

edited 20 May 2025 by m_haraldsen — expanded the table to cover the lower concentration

Put another way, the half-life is a formulation achievement rather than an intrinsic property. Native GLP-1 has a plasma half-life of a couple of minutes; everything in this class is a set of modifications engineered to defeat that.

The GIP agonism-versus-antagonism question remains open, and the awkward fact is that both directions have produced weight loss in humans. The reconciling hypothesis is that chronic GIPR agonism produces receptor desensitisation and therefore functions as a pharmacological antagonist, but that is a hypothesis fitted to the data rather than an independent finding.

Oral bioavailability of a 4 kDa peptide is essentially zero without help. Oral semaglutide is co-formulated with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, which raises local gastric pH and transiently increases transcellular permeability in a small area of gastric mucosa. It works, and it delivers roughly one per cent of the dose, which is why the oral tablet strengths are an order of magnitude above the injectable and why fasting and water volume are not optional details.

The structural basis of semaglutide’s pharmacokinetics — Aib-8, the Arg34Lys substitution and the C18 diacid–AEEA linker at Lys26 — is described in the original medicinal chemistry publication, and it is worth reading once because it makes the design logic explicit[1].

I would separate what is established structurally from what is inferred clinically. The chemistry is settled; the attribution of clinical effect to specific receptor arms mostly is not.

If you want to reason about a new agent, start from its receptor profile and its half-life. Almost everything else follows.

The part that matters: the mechanism question has a clean answer for the peripheral effects and a much less clean answer for the central ones, and it is worth being explicit about which of those you are asking about.

Comparing a 2.4 mg dose of one agonist to a 15 mg dose of another tells you nothing, because the molar potencies at their respective receptors differ, the receptor profiles differ, and the exposure per milligram differs. The only defensible comparison is between clinical outcomes in trials with comparable populations and durations, which is why SURMOUNT-5 exists and why indirect comparisons should be read sceptically.

The caveat is that mechanism explains and does not predict. A clean mechanistic story has repeatedly failed to survive a Phase 3 in metabolic medicine.

The mechanism is settled enough to be useful and unsettled enough to be interesting, which is a reasonable place for a field to be.

Dose equivalence across agents with different receptor profiles is not a defensible concept, and the attempt to construct it is the most common analytical error in this area.

Tirzepatide is an imbalanced dual agonist: it is more potent at the GIP receptor than at the GLP-1 receptor, which is the opposite of what most people assume from the way it is described. Whether the GIP contribution works through central appetite pathways, through adipose insulin sensitisation, or through modulating the GLP-1 signal is genuinely unsettled, and the honest position is that the clinical result is clear and the attribution is not.

Retatrutide’s Phase 2 dose-ranging results reported dose-dependent weight reduction with a tri-agonist across a range of doses, and the magnitude at the top dose is what motivated the Phase 3 TRIUMPH programme[1].

Do not convert doses between agents. There is no exchange rate, and constructing one is how people arrive at an order-of-magnitude error.

edited 22 Mar 2025 by s_kalniete — tightened the wording; no substantive change